GRAIL, Inc. is a biotechnology company focused on cancer screening and early detection. The company's core technology analyzes cell-free DNA (cfDNA) in blood samples using high-intensity genomic sequencing and machine learning algorithms to detect cancer-specific methylation patterns. Its flagship product, the Galleri multi-cancer early detection test, is designed to screen for more than 50 types of cancer and predict the tissue of origin to guide subsequent diagnostic evaluations.
GRAIL generates the vast majority of its revenue from its screening segment. In the first quarter of 2025, the company reported $31.8 million in total revenue, with approximately 91.5% ($29.1 million) derived from screening revenue, primarily driven by sales of the Galleri test in the United States. The remaining 8.5% ($2.7 million) came from development services provided to biopharmaceutical and clinical customers. GRAIL distributes its tests through direct sales channels and strategic partnerships with healthcare providers, health systems, and employers. Originally founded in 2015 as a subsidiary of Illumina, GRAIL was spun off as an independent publicly traded company in June 2024. The company operates a CLIA-certified laboratory and conducts extensive population-scale clinical studies to validate its technology and secure broader reimbursement coverage.
